Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.6052W HIGH $28.44
Volume
8.95 K
Value Traded
62.96 K
Short % Float
0.26%
-2.44%Week
-38.05%1 Month
-50%3 Month
-69.7%6 Month
-99.69%5 Year
-99.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
22.39 M
EPS (TTM)
-1.09
P/E Ratio
-
Ent. Value
18.60 M
Total Shares
8.00 M
Float Shares
4.15 M
Insiders
48.12%
Institutions
17.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PAVM Catalyst Timeline
Dated clinical, regulatory and corporate events for PAVmed Inc.
Past FDA Catalysts and PDUFA Decisions
How PAVM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
PAVmed Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PAVM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| esophageal precancer detection | 2021-05-24 | total samples: 79; positive samples: 18; negative samples: 54; not evaluable samples: 7; positive percentage: 22.8%; negative percentage: 68.4%; not evaluable percentage: 8.7%Read More | Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics' EsoCheck and EsoGuard Technologies Initial NYU experience in 99 patients demonstrated EsoCheck and EsoGuard cRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Aklog LishanDirector, Officer (Chairman and CEO) | Grant/Award | 350,000 357,614 held | $0.00 | 04/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PAVM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PAVM for Q2 2026. | ||||
PAVM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PAVM ranks across every disease it competes in
Competitive Position is a premium feature
See how PAVM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPAVM News
PAVM▲ +9.7%on this news
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
PAVmed Inc. provided a business update and reported its second quarter 2026 financial results, highlighting significant advancements in its subsidiaries. Veris Health is progressing towards an FDA submission for its implantable monitor, while Lucid Diagnostics secured a crucial coverage policy for its EsoGuard test. Despite a reported net loss, the company noted positive developments across its product portfolio.
Read more →PAVMPAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
PAVmed Inc. has announced a business update conference call scheduled for August 14, 2026. The call will feature CEO Lishan Aklog discussing the company's operations and growth strategy, along with CFO Dennis McGrath presenting the second quarter 2026 financial results. The event will be accessible via webcast and telephone.
Read more →PAVMPAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
PAVmed Inc. provided a business update and reported its financial results for Q1 2026. The company is making strides in expanding its commercial opportunities, particularly with Veris Health's implantable physiological monitor nearing FDA submission. Lucid Diagnostics experienced revenue growth from the EsoGuard test and strengthened its financial position. However, PAVmed also reported a notable net loss of $7.0 million along with increased operating expenses in the first quarter.
Read more →PAVMPAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
PAVmed Inc. will host a business update conference call and webcast on May 15, 2026, at 8:30 AM ET. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company's operations and first quarter 2026 financial results. The event will be accessible via the company's website and by telephone.
Read more →PAVM▲ +13%on this news
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PAVmed Inc. reported its fourth quarter and full year 2025 financial results, highlighting strengthened capital structure and relaunch of its medical device portfolio. The company is advancing partnerships, including with The Ohio State University for its Veris division, which is progressing towards FDA submission. A positive financial outlook is seen with the expansion of EsoGuard's access, notably through a contract with the U.S. Department of Veterans Affairs. Overall, PAVmed is well-positioned for growth after addressing legacy financial challenges.
Read more →PAVMPAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026
PAVmed Inc. has announced a business update conference call and webcast scheduled for March 30, 2026. The call will feature CEO Lishan Aklog discussing the company's operations and growth strategy, alongside CFO Dennis McGrath presenting the fourth quarter 2025 financial results. The event reflects PAVmed's commitment to transparency and engagement with its stakeholders.
Read more →PAVM▲ +7.2%on this news
PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities
PAVmed Inc. has announced the successful closing of preferred stock and senior secured note financings, resulting in the elimination of its previously outstanding convertible securities. This transaction raised $30 million from a Series D Preferred Stock offering and an additional $15 million through a senior secured note, significantly enhancing the company's balance sheet. The company plans to seek stockholder approval for the conversion of the Series D Preferred Stock into common stock at a special meeting by April 30, 2026. This strategic move aims to transform PAVmed's capital structure into a more streamlined composition of common stock and long-term debt.
Read more →PAVM▼ -16.7%on this news
PAVmed Announces Reverse Stock Split
PAVmed Inc. has announced a 1-for-30 reverse stock split of its common stock, effective January 2, 2026. This move aims to comply with Nasdaq's minimum bid price requirement. The approved split was confirmed by the company's shareholders during a special meeting in December 2025. As a result of this action, authorized shares will decrease significantly, impacting various equity incentives and outstanding convertible securities.
Read more →PAVM▼ -8.5%on this news
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
PAVmed Inc. reported its third quarter 2025 financial results while providing a business update on its subsidiaries. Noteworthy developments include the launch of the commercial phase of a strategic partnership with Veris Health, which aims to bring its implantable physiological monitor to market, and advancements in Medicare coverage for Lucid Diagnostics' EsoGuard test. The company also signed a letter of intent to license advanced endoscopic imaging technology. However, PAVmed continues to face significant operating losses despite recent improvements in its balance sheet.
Read more →PAVMPAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results
PAVmed Inc. has provided a business update alongside the financial results for the second quarter of 2025. The company recognized revenue of $1.2 million from its EsoGuard tests and announced a meeting with CAC regarding Medicare LCD for EsoGuard scheduled for September 4. Despite positive developments, such as completed financings for its subsidiaries and advancements in product development, PAVmed also reported significant losses and high operating expenses, reflecting ongoing financial challenges. The company's leadership expressed optimism about meeting near-term milestones and exploring new business opportunities.
Read more →PAVM▼ -13.7%on this news
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
PAVmed Inc. provided a business update and financial results for the first quarter of 2025, highlighting a capital acquisition that extends its runway beyond key reimbursement milestones. The company ended the quarter with over $40 million in proforma cash. Notably, PAVmed announced a commercial partnership with a major cancer center and resumed the development of an implantable physiological monitor. Despite these advancements, the company reported a net loss of $18.6 million, and revenue significantly declined compared to the prior year.
Read more →PAVM▼ -5.1%on this news
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
PAVmed Inc. has provided a business update and reported its financial results for the fourth quarter and full year of 2024. The company processed a record volume of diagnostic tests and experienced rapid uptake in concierge medicine contracts, along with securing its first commercial insurance coverage. Key financial improvements include successfully completing debt restructuring and regaining Nasdaq compliance. The company's subsidiaries, Lucid Diagnostics and Veris Health, are positioned to enhance PAVmed's long-term success as they advance their respective commercial strategies.
Read more →PAVM▲ +6.9%on this news
PAVmed Provides Business Update and Third Quarter 2024 Financial Results Lucid reports record quarterly EsoGuard revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage
PAVmed Inc. has provided a business update and reported its financial results for the third quarter of 2024. The company achieved record revenue of $1.2 million for its EsoGuard tests and is preparing to submit clinical evidence for Medicare coverage. Additionally, PAVmed highlighted the completion of a deconsolidation process aimed at regaining Nasdaq compliance, although it faced a substantial net loss this quarter. The company's subsidiaries are actively pursuing growth initiatives and partnerships.
Read more →PAVMPAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors
PAVmed Inc. announced efforts to regain compliance with Nasdaq listing requirements, which include the deconsolidation of Lucid Diagnostics from its financial statements. This change enhances PAVmed's balance sheet by removing Lucid's operating losses from its consolidated financials. The company appointed Sundeep Agrawal, M.D., a seasoned biotech investor, to its board while replacing two departing directors. PAVmed remains committed to exploring alternatives to improve stockholder equity as it requests a hearing from Nasdaq regarding its listing status.
Read more →PAVM▼ -7.5%on this news
PAVmed Provides Business Update and Second Quarter 2024 Financial Results Lucid reports record quarterly EsoGuard test volume and held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's M
PAVmed Inc. has released its business update and financial results for the second quarter of 2024, indicating a record volume for EsoGuard tests and an active pursuit of financing. The company aims to strengthen its financial position by making each of its subsidiaries financially independent. Despite revenue growth, PAVmed reported considerable operating losses, which reflects ongoing financial pressure. Lucid Diagnostics is highlighted as a strong asset within the company's portfolio, showing significant commercial progress.
Read more →PAVM▲ +15.6%on this news
PAVmed Provides Business Update and First Quarter 2024 Financial Results Lucid strengthens balance sheet and secures a
PAVmed Inc. provided a business update and financial results for the first quarter of 2024, highlighting substantial growth in revenue from its subsidiary, Lucid Diagnostics. Lucid reported $1.0 million in EsoGuard revenue, marking a 124% increase from the previous year. The company successfully completed a $29.8 million Series B Preferred Stock Offering, which has strengthened its financial position. However, PAVmed recorded a net loss of approximately $22.8 million, raising questions about its operating expenses and overall financial sustainability.
Read more →PAVM▲ +17%on this news· ran to +35% by day 1
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Parties to implement a pilot program of
PAVmed Inc. announced that its subsidiary Veris Health has signed a memorandum of understanding with The Ohio State University Comprehensive Cancer Center to implement a pilot program utilizing the Veris Cancer Care Platform. This initiative intends to enhance personalized cancer care through advanced digital health tools, including remote monitoring and telehealth capabilities. PAVmed's executives expressed excitement about working with such a renowned institution, emphasizing the potential benefits for cancer patients receiving systemic therapy. The Veris platform is designed to improve patient outcomes, reduce complications, and aid in overall cancer treatment strategies.
Read more →PAVM▲ +8.3%on this news
Madison Avenue, 25th Floor New York, New York 10017
PAVmed Inc. has announced the approval of a special dividend distribution of approximately 3,331,771 shares of Lucid Diagnostics Inc. to its stockholders. This distribution represents about 6.9% of Lucid Diagnostics' outstanding common stock. Each PAVmed stockholder will receive approximately 0.377 shares of Lucid Diagnostics for every share of PAVmed they hold, with the distribution date set for February 15, 2024. Furthermore, PAVmed will retain a significant 65.2% ownership in Lucid Diagnostics post-distribution.
Read more →PAVM▼ -19.4%on this news· ran to -36% by day 3
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split PAVmed shareholders as of
PAVmed Inc. announced a dividend distribution of around 3.3 million shares of its subsidiary, Lucid Diagnostics, to shareholders on January 15, 2024. This move is part of the repayment of intercompany debt owed to PAVmed by Lucid. Additionally, PAVmed revealed a 1-for-15 reverse stock split effective December 7, 2023, aimed at maintaining compliance with Nasdaq listing requirements. The reverse stock split will also reduce the authorized shares of PAVmed's common stock significantly.
Read more →PAVMPAVmed Provides Business Update and Third Quarter Financial Results Lucid's quarterly revenue increased 392 percent sequentially Veris Health commercial expansion efforts underway, with next-generation Veris Cancer Care
PAVmed Inc. has released a business update alongside its third quarter financial results, noting a remarkable 392% sequential increase in quarterly revenue. This update underscores the significant role of its subsidiary, Lucid Diagnostics, which is achieving increased commercial activity and revenue growth. Additionally, Veris Health is gearing up to launch its upgraded Cancer Care Platform in the fourth quarter. The company remains optimistic about its future prospects, driven by improved commercial execution across its business units.
Read more →About PAVmed Inc.
Headquarters360 MADISON AVENUE, NEW YORK, NY, 10017
BIOPHARMAWATCH ELITE PLUS
Trade the next PAVM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime